Login to Your Account

Isis' Antisense Drug Fizzles In Crohn's But Beats Colitis

By Randall Osborne

Friday, December 3, 2004
The second Phase III failure of an antisense drug in a week - this time, Isis Pharmaceuticals Inc.'s first-generation alicaforsen for Crohn's disease - might have cast some doubt on the once-ballyhooed field, but Isis is sticking with the compound for ulcerative colitis on the basis of success in three Phase II studies. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription